<?xml version="1.0" encoding="UTF-8"?>
<p id="para0019">The efficacy of IL-6â€“IL-6R antagonists for the treatment of CRS as well as sHLH underscores the central role of IL-6 signaling in the pathophysiology of cytokine-driven hyperinflammatory syndromes 
 <xref rid="bib0022" ref-type="bibr">[22]</xref>
 <italic>.</italic> Severe COVID-19 cases may benefit from IL-6 pathway inhibition given the associated CRS- and sHLH-like serum cytokine elevations 
 <xref rid="bib0003" ref-type="bibr">[3]</xref>.
</p>
